Breaking News: 1910 Genetics Secures $26.7 Million in Funding from Top Investors

1910 Genetics has successfully raised an impressive $26.7 million in its latest funding round, a significant milestone that underscores the company's pivotal role in the biotechnology industry. As the only company focused on enhancing small and large molecule drug discovery through a multimodal AI platform powered by laboratory automation, 1910 Genetics is well-positioned to transform how new therapies are developed. With a cutting-edge approach that integrates artificial intelligence with three distinct data streams—computational data, wet lab proxy biological data, and wet lab ground truth biological data—1910 Genetics is dedicated to delivering novel drug candidates and innovative software solutions to leading pharmaceutical and technology partners. The funds raised will be directed towards advancing the company’s internal pipeline targeting critical areas such as neurological and autoimmune diseases, as well as cancer treatment. This latest investment round saw participation from prominent backers, including M12 - Microsoft's Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures, and Scientia Ventures, highlighting a strong belief in the transformative potential of 1910 Genetics' technology. With this new capital, the company is poised to further develop its proprietary platforms, engage with its partners more effectively, and ultimately contribute to the faster discovery and development of life-saving therapies for patients in need. The future looks promising as 1910 Genetics aims to set a new standard in drug development through its innovative use of AI and automation in biomedicine.